Sétien A A, Brochier B, Tordo N, De Paz O, Desmettre P, Péharpré D, Pastoret P P
Unitad de Investigacion Médica en Immunologia, Instituto Mexicano del Seguro Social, México D.F., México.
Vaccine. 1998 Jul;16(11-12):1122-6. doi: 10.1016/s0264-410x(98)80108-4.
A rabies virus variant isolated from a vampire bat (Desmodus rotundus) and characterized by genome sequencing was used for the standardization of an experimental infection in this species. The parenteral administration of 10(6) MICLD50 of this variant was capable of inducing death from rabies in 89% of animals. The mean duration of post-challenge survival was 12 days. None of the experimental rabid vampire bats showed aggressive behaviour. A vaccinia-rabies glycoprotein recombinant virus vaccine was administered orally to vampire bats on days -120, -90, -30 or -18 pre-challenge, on the same day of challenge, or on day +5 post-challenge. A significant protection was noticed only in animals vaccinated on days -18 or -30 pre-challenge. A longer period of incubation was observed in animals vaccinated 5 days post-challenge.
从吸血蝙蝠（圆叶吸血蝠）中分离出并通过基因组测序鉴定的一种狂犬病病毒变种，被用于该物种实验性感染的标准化。对该变种采用肠胃外途径给予10(6)半数感染剂量（MICLD50），能够使89%的动物因狂犬病死亡。攻击后存活的平均时长为12天。实验感染的吸血蝙蝠均未表现出攻击行为。在攻击前第-120、-90、-30或-18天、攻击当天或攻击后第+5天，给吸血蝙蝠口服痘苗狂犬病糖蛋白重组病毒疫苗。仅在攻击前第-18或-30天接种疫苗的动物中观察到显著的保护作用。在攻击后5天接种疫苗的动物中观察到潜伏期更长。
